Search for: "VIATRIS INC." Results 1 - 10 of 10
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Sep 2023, 4:53 am by Alan Rosca
Securities attorneys Alan Rosca, Paul Scarlato, and Kathryn Weidner have been investigating potential securities violations and corporate misconduct, as well as questionable business practices involving Viatris, Inc. and have identified potential areas of concern for Viatris investors. [read post]
29 Sep 2023, 4:53 am by Alan Rosca
Securities attorneys Alan Rosca, Paul Scarlato, and Kathryn Weidner have been investigating potential securities violations and corporate misconduct, as well as questionable business practices involving Viatris, Inc. and have identified potential areas of concern for Viatris investors. [read post]
29 Sep 2023, 4:53 am by Alan Rosca
Securities attorneys Alan Rosca, Paul Scarlato, and Kathryn Weidner have been investigating potential securities violations and corporate misconduct, as well as questionable business practices involving Viatris, Inc. and have identified potential areas of concern for Viatris investors. [read post]
10 Nov 2022, 1:25 pm by Mark Astarita
The Securities and Exchange Commission today announced insider trading charges against Ramkumar Rayapureddy, Chief Information Officer of pharmaceutical company Viatris Inc., which was formerly known as Mylan N.V. [read post]
8 Mar 2022, 7:39 am by Zak Gowen
  Viatris Agrees to Settle EpiPen Antitrust Litigation for $264 Million. [read post]
14 Nov 2022, 12:15 am
Last week, the Securities and Exchange Commission announced that it had filed a complaint against the Chief Information Officer of pharmaceutical company Viatris Inc. [read post]
15 Aug 2022, 3:10 am by Moll Law Group
Early in July, Mylan Pharmaceuticals, Inc. voluntarily recalled a batch of its prefilled Insulin Glargine Injection pens that come in 100 units/mL, 3 mL. [read post]
5 Apr 2023, 5:18 am by Annsley Merelle Ward
Marcus Smith upheld his earlier finding that the patent was valid and therefore granted an injunction in Neurim v Generics (UK) Ltd (t/a Viatris) [2022] EWHC 512 (Pat). [read post]